MedTrace Logo

BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study

NCT02936492 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-11-08

No results posted yet for this study

Summary

Systemic safety following single and multiple dermal administration of BAY1003803

Conditions

Interventions

DRUG

BAY1003803 0.01% lipophilic cream

Topical administration for 22 h per day

DRUG

BAY1003803 0.1% lipophilic cream

Topical administration for 22 h per day

DRUG

BAY1003803 0.01% ointment

Topical administration for 22 h per day

DRUG

BAY1003803 0.1% ointment

Topical administration for 22 h per day

DRUG

Lipophilic cream vehicle

Topical administration for 22 h per day

DRUG

Ointment vehicle

Topical administration for 22 h per day

DRUG

Clobetasol propionate

Topical administration for 22 h per day

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-24
Primary Completion
2017-04-18
Completion
2017-10-16

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02936492 on ClinicalTrials.gov